LWA
CUE icon

Lenox Wealth Advisors’s Cue Biopharma CUE Stock Holding History

Lenox Wealth Advisors’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$1K Hold
3
– – ﹤0.01% 696
2021
Q4 		$1K Hold
3
– – ﹤0.01% 821
2021
Q3 		$1K Hold
3
– – ﹤0.01% 657
2021
Q2 		$1K Hold
3
– – ﹤0.01% 662
2021
Q1 		$1K Hold
3
– – ﹤0.01% 645
2020
Q4 		$1K Hold
3
– – ﹤0.01% 591
2020
Q3 		$2K Hold
3
– – ﹤0.01% 508
2020
Q2 		$2K Buy
+3
New +$2.17K ﹤0.01% 510

Other funds holding CUE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lenox Wealth Advisors's CUE Position: Q1 2022 in Review

Lenox Wealth Advisors held its Cue Biopharma (CUE) position steady in Q1 2022 at 3 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #696.

Lenox Wealth Advisors first reported a position in CUE in Q2 2020 and has held it in 8 quarters since. The position peaked at $2K in Q3 2020. 100 funds tracked by Wall St. Rank hold CUE as of Q1 2022.

  • Lenox Wealth Advisors held 3 shares of Cue Biopharma worth $1K as of Q1 2022.
  • Lenox Wealth Advisors left its Cue Biopharma share count unchanged in Q1 2022.
  • Cue Biopharma made up ﹤0.01% of Lenox Wealth Advisors's portfolio in Q1 2022, its #696 holding.
  • Lenox Wealth Advisors first reported a position in Cue Biopharma in Q2 2020 and has held it in 8 quarters since.
  • Lenox Wealth Advisors's Cue Biopharma position peaked at $2K in Q3 2020.
  • 100 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2022.

Based on Lenox Wealth Advisors's 13F filing for Q1 2022, filed 14 Apr 2022.